香港股市 已收市

MRK Jan 2024 140.000 put

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
27.910.00 (0.00%)
收市價: 03:24PM EST
全螢幕
前收市價27.91
開市28.03
買盤32.75
賣出價33.60
拍板140.00
到期日2024-01-19
今日波幅27.91 - 28.04
合同範圍
成交量80
未平倉合約81
  • Benzinga

    Merck's Keytruda Plus Chemo Combo Aces Late-Stage Study In Advanced Endometrial Cancer Patients

    Merck & Co Inc's (NYSE: MRK) Phase 3 NRG-GY018 trial evaluating Keytruda (pembrolizumab) combined with standard-of-care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival (PFS). The trial covered patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status. Related: Merck's Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients. The treatment regime included Keytruda + Chemo combo, then continued

  • Benzinga

    Merck's Oral COVID-19 Treatment Might Be Linked To Spreading Mutations, Study Shows

    According to some researchers, Merck & Co’s (NYSE: MRK) COVID-pill is giving rise to new mutations of the COVID-19 virus in some patients. Mutations linked to Merck’s COVID-19 oral treatment Lagevrio (Molnupiravir) have been identified in viral samples taken from several patients, according to a preprint study from researchers in the U.S. and at the Francis Crick Institute, Imperial College London, and other U.K. institutions. Also Read: Merck Beats On Q4 earnings, Anticipates Almost 80% Decline

  • AASTOCKS

    《大行報告》大摩微降默沙東(MRK.US)目標價至99美元 評級「與大市同步」

    摩根士丹利發表報告指,默沙東(MRK.US)去年第四季收入及每股盈利表現優於市場預期,今年首次收入指引亦於市場預期內,但每股盈利指引則低於預期,主要由於毛利率較低及稅率上升。 該行認為,集團去年的業務勢頭料可延續至今年,並預計其毛利率將於明年有所擴展。而集團股價昨日(2日)下跌3.3%,對比標指為上升1.5%,相信主要由於股市出現更廣泛的板塊輪換,離開防守性股份,市場重組倉位及對其每股盈利指引感混亂所致。 大摩微降默沙東美股目標價,由100美元降至99美元,評級維持「與大市同步」。(ek/da)~ 阿思達克財經新聞 網址: www.aastocks.com